Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8BSF3)

Drug Name

HuMax-TAC Drug Info

Synonyms

Anti-IL-2R antibody, Genmab/Merck Serono

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Terminated	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin 2 receptor alpha (IL2RA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Basiliximab	DMWNRZT	Organ transplant rejection	NE84	Approved	[3]
Inolimomab	DMUS1F8	Heart transplant rejection	NE84	Phase 3	[4]
RFT-5.dgA	DMQ8K93	Human immunodeficiency virus infection	1C62	Phase 2	[5]
LMB-2	DMG7RAV	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[6]
CHT-25	DMJLZ8T	Hodgkin lymphoma	2B30	Phase 1	[7]
RG6292	DMBRYZ7	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 2 receptor alpha (IL2RA)	TT10Y9E	IL2RA_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018175)
2	Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines. Med Res Rev. 2012 Mar;32(2):254-93.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease.Biol Blood Marrow Transplant.2006 Nov;12(11):1135-41.
5	Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol. 2003 May;14(5):729-36.
6	Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36.
7	A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. Clin Cancer Res. 2009 Dec 15;15(24):7701-7710.
8	Clinical pipeline report, company report or official report of Roche.